{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:28:13Z","timestamp":1790180893816,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC 109-2923-B-001-002-MY3"],"award-info":[{"award-number":["NSTC 109-2923-B-001-002-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jconrel.2025.114042","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T18:26:29Z","timestamp":1752603989000},"page":"114042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Antitumor efficacy achieved by targeting PEGylated nanomedicines to netrin-1 in the extracellular matrix or EphA2 on the cancer cell membrane"],"prefix":"10.1016","volume":"385","author":[{"given":"Po-Chuan","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trieu Thi My","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Wen","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Hung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Sze","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lin","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Gibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve R.","family":"Roffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114042_bb0005","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/028418600430789","article-title":"High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas: rationale for combination with radiotherapy","volume":"39","author":"Koukourakis","year":"2000","journal-title":"Acta Oncol."},{"key":"10.1016\/j.jconrel.2025.114042_bb0015","doi-asserted-by":"crossref","first-page":"15344","DOI":"10.1073\/pnas.1411499111","article-title":"Investigating the optimal size of anticancer nanomedicine","volume":"111","author":"Tang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2025.114042_bb0020","doi-asserted-by":"crossref","first-page":"12281","DOI":"10.1021\/acsnano.9b09713","article-title":"What went wrong with anticancer nanomedicine design and how to make it right","volume":"14","author":"Sun","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.114042_bb0025","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1158\/1078-0432.CCR-08-2392","article-title":"Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody","volume":"15","author":"ElBayoumi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jconrel.2015.10.044","article-title":"Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin","volume":"220","author":"Arabi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114042_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15507","article-title":"Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy","volume":"8","author":"Su","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114042_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11671-020-03334-9","article-title":"Anti-Epcam aptamer (Syl3c)-functionalized liposome for targeted delivery of doxorubicin: in vitro and in vivo antitumor studies in mice bearing C26 colon carcinoma","volume":"15","author":"Mashreghi","year":"2020","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2025.114042_bb0045","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2217\/nnm.12.160","article-title":"EGF receptor-targeted nanocarriers for enhanced cancer treatment","volume":"7","author":"Master","year":"2012","journal-title":"Nanomed"},{"key":"10.1016\/j.jconrel.2025.114042_bb0050","first-page":"401","article-title":"Functionalized liposomes for targeted breast cancer drug delivery","volume":"24","author":"Nel","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2025.114042_bb0055","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jconrel.2023.05.032","article-title":"Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: a review","volume":"359","author":"Beishenaliev","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114042_bb0060","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-20-0853","article-title":"A novel antibody\u2013IL15 fusion protein selectively localizes to tumors, synergizes with TNF-based immunocytokine, and inhibits metastasis","volume":"20","author":"Corbellari","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2025.114042_bb0065","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-22-1532","article-title":"Proteomic profiling of extracellular matrix components from patient metastases identifies consistently elevated proteins for developing nanobodies that target primary tumors and metastases","volume":"83","author":"Jailkhani","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41568-020-00329-7","article-title":"The matrix in cancer","volume":"21","author":"Cox","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.114042_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg3840","article-title":"The extracellular matrix as hallmark of cancer and metastasis: from biomechanics to therapeutic targets","volume":"16","author":"Sleeboom","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.114042_bb0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nature02788","article-title":"Netrin-1 controls colorectal tumorigenesis by regulating apoptosis","volume":"431","author":"Mazelin","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.114042_bb0085","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1158\/0008-5472.CAN-14-3652","article-title":"Dependence receptors and cancer: addiction to trophic ligands","volume":"75","author":"Gibert","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0090","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1073\/pnas.0709810105","article-title":"Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer","volume":"105","author":"Fitamant","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2025.114042_bb0095","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrc3005","article-title":"Novel roles for slits and netrins: axon guidance cues as anticancer targets?","volume":"11","author":"Mehlen","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.114042_bb0100","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1158\/0008-5472.CAN-18-2952","article-title":"Cancer-associated fibroblasts produce netrin-1 to control cancer cell plasticity","volume":"79","author":"Sung","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0105","doi-asserted-by":"crossref","first-page":"16210","DOI":"10.1073\/pnas.0405984101","article-title":"The axonal attractant Netrin-1 is an angiogenic factor","volume":"101","author":"Park","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2025.114042_bb0110","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1053\/j.gastro.2009.12.061","article-title":"Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells","volume":"138","author":"Dumartin","year":"2010","journal-title":"Gastroenterol"},{"key":"10.1016\/j.jconrel.2025.114042_bb0115","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41586-023-06372-2","article-title":"Pharmacological targeting of netrin-1 inhibits EMT in cancer","volume":"620","author":"Lengrand","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.114042_bb0120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41586-023-06367-z","article-title":"Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer","volume":"620","author":"Cassier","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.114042_bb0125","first-page":"613","article-title":"Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival","volume":"9","author":"Kinch","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0130","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1158\/1078-0432.CCR-03-0589","article-title":"EphA2 expression is associated with aggressive features in ovarian carcinoma","volume":"10","author":"Thaker","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0135","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/1078-0432.CCR-15-0603","article-title":"EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer","volume":"22","author":"Dunne","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0140","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/s41388-021-01714-8","article-title":"Oncogenic functions and therapeutic targeting of EphA2 in cancer","volume":"40","author":"Wilson","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2025.114042_bb0145","doi-asserted-by":"crossref","first-page":"9367","DOI":"10.1158\/0008-5472.CAN-08-1933","article-title":"A human antibody\u2013drug conjugate targeting EphA2 inhibits tumor growth in vivo","volume":"68","author":"Jackson","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0150","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13045-020-00944-9","article-title":"Targeting EphA2 in cancer","volume":"13","author":"Xiao","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114042_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04225-5","article-title":"Reversible glycosidic switch for secure delivery of molecular nanocargos","volume":"9","author":"Burnouf","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114042_bb0160","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/sj.bjc.6600317","article-title":"Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice","volume":"86","author":"Prijovich","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.114042_bb0165","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0006-2952(03)00472-6","article-title":"Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin","volume":"66","author":"Prijovich","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114042_bb0170","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114042_bb0175","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.114042_bb0180","first-page":"608","article-title":"Characterization of a newly established human bladder carcinoma cell line, NTUB1","volume":"91","author":"Yu","year":"1992","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.jconrel.2025.114042_bb0185","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1165\/ajrcmb.17.3.2837","article-title":"Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line","volume":"17","author":"Chu","year":"1997","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2025.114042_bb0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1158\/1078-0432.173.11.1","article-title":"Prognosis of non\u2013small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes","volume":"11","author":"Sher","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0195","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/djq279","article-title":"Lung cancer cell lines as tools for biomedical discovery and research","volume":"102","author":"Gazdar","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2025.114042_bb0200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ijc.2910250104","article-title":"Characterization of a human ovarian teratocarcinoma-derived cell line","volume":"25","author":"Zeuthen","year":"1980","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.114042_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-020-00752-w","article-title":"Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity","volume":"19","author":"Ho","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.114042_bb0210","doi-asserted-by":"crossref","first-page":"140138","DOI":"10.1016\/j.ijbiomac.2025.140138","article-title":"Targeted internalization and activation of glycosidic switch liposomes by a biological macromolecule mPEG\u00d7 EphA2 increases therapeutic efficacy against lung cancer","volume":"300","author":"Ho","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2025.114042_bb0215","doi-asserted-by":"crossref","first-page":"ra57","DOI":"10.1126\/scisignal.2002456","article-title":"Nucleolar localization of a netrin-1 isoform enhances tumor cell proliferation","volume":"5","author":"Delloye-Bourgeois","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.jconrel.2025.114042_bb0220","first-page":"1203","article-title":"ANXA1-derived peptides suppress gastric and colon cancer cell growth by targeting EphA2 degradation corrigendum in 10.3892\/ijo.2020.5149","volume":"57","author":"Feng","year":"2020","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jconrel.2025.114042_bb0225","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/bios5010098","article-title":"Label-free detection of rare cell in human blood using gold nano slit surface plasmon resonance","volume":"5","author":"Mousavi","year":"2015","journal-title":"Biosensors"},{"key":"10.1016\/j.jconrel.2025.114042_bb0230","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.1016\/j.biomaterials.2014.08.032","article-title":"One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles","volume":"35","author":"Kao","year":"2014","journal-title":"Biomater"},{"key":"10.1016\/j.jconrel.2025.114042_bb0235","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12645-023-00230-6","article-title":"Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG\u00d7 CD20)","volume":"14","author":"Chen","year":"2023","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.114042_bb0240","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41551-021-00698-w","article-title":"The evolution of commercial drug delivery technologies","volume":"5","author":"Vargason","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2025.114042_bb0245","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/ijc.21677","article-title":"Fibronectin as target for tumor therapy","volume":"118","author":"Kaspar","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.114042_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.01.029","article-title":"Chemotherapeutic drug delivery by tumoral extracellular matrix targeting","volume":"274","author":"Raav\u00e9","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114042_bb0255","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.molmed.2021.07.009","article-title":"Extracellular matrix-based cancer targeting","volume":"27","author":"Karamanos","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2025.114042_bb0260","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.cgt.7700999","article-title":"Membrane-localized activation of glucuronide prodrugs by \u03b2-glucuronidase enzymes","volume":"14","author":"Chen","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2025.114042_bb0265","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/tra.12123","article-title":"EphA2 signaling following endocytosis: role of Tiam1","volume":"14","author":"Boissier","year":"2013","journal-title":"Traffic"},{"key":"10.1016\/j.jconrel.2025.114042_bb0270","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1158\/1535-7163.MCT-09-0899","article-title":"Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy","volume":"9","author":"Chuang","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2025.114042_bb0275","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.nano.2015.06.007","article-title":"In vitro experiments showing enhanced release of doxorubicin from Doxil (R) in the presence of ammonia may explain drug release at tumor site","volume":"11","author":"Silverman","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.jconrel.2025.114042_bb0280","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1172\/JCI69600","article-title":"Glutamine and cancer: cell biology, physiology, and clinical opportunities","volume":"123","author":"Hensley","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2025.114042_bb0285","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/sj.bjc.6600423","article-title":"Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes","volume":"87","author":"Marty","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.114042_bb0290","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ijc.10821","article-title":"Quantification of expression of netrins, slits and their receptors in human prostate tumors","volume":"103","author":"Latil","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.114042_bb0295","doi-asserted-by":"crossref","first-page":"17146","DOI":"10.1073\/pnas.0901767106","article-title":"Netrin-1 up-regulation in inflammatory bowel diseases is required for colorectal cancer progression","volume":"106","author":"Paradisi","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2025.114042_bb0300","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317698388","article-title":"Netrin-1 in cancer: potential biomarker and therapeutic target?","volume":"39","author":"Kefeli","year":"2017","journal-title":"Tumour Biol."},{"key":"10.1016\/j.jconrel.2025.114042_bb0305","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/2326-6066.CIR-18-0622","article-title":"Antibody\u2013cytokine fusions: versatile products for the modulation of anticancer immunity","volume":"7","author":"Neri","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0310","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41423-021-00786-6","article-title":"The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy","volume":"19","author":"Zheng","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2025.114042_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0925-5710(98)00039-5","article-title":"PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques","volume":"68","author":"Francis","year":"1998","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jconrel.2025.114042_bb0320","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jconrel.2011.05.027","article-title":"PEGylation improves pharmacokinetic profile, liver uptake and efficacy of interferon gamma in liver fibrosis","volume":"154","author":"Bansal","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114042_bb0325","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41551-021-00797-8","article-title":"Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells","volume":"5","author":"Zhang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2025.114042_bb0330","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nrc2247","article-title":"Carboxypeptidase G2-based gene-directed enzyme\u2013prodrug therapy: a new weapon in the GDEPT armoury","volume":"7","author":"Hedley","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.114042_bb0335","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1021\/bc1005784","article-title":"A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment","volume":"22","author":"Chen","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.114042_bb0340","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1021\/mp300581u","article-title":"Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue","volume":"10","author":"Chen","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.114042_bb0345","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jconrel.2024.02.026","article-title":"Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs","volume":"369","author":"Tseng","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114042_bb0350","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1158\/1538-7445.AM2015-2921","article-title":"Preclinical characteristics of NP137, a first-in-class monoclonal antibody directed against netrin-1 and inducing dependence receptors-mediated cell death","volume":"75","author":"Ducarouge","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2024.213881","article-title":"Anti-Netrin-1 decorated nanoparticles combined with chemotherapy for the treatment of triple-negative breast cancer","volume":"161","author":"Breusa","year":"2024","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.jconrel.2025.114042_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-025-00757-3","article-title":"Extracellular matrix: unlocking new avenues in cancer treatment","volume":"13","author":"Lee","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0365","doi-asserted-by":"crossref","first-page":"11745","DOI":"10.1158\/0008-5472.CAN-06-2322","article-title":"Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH2-terminal kinase 1 and up-regulating N-cadherin expression","volume":"66","author":"Shintani","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114042_bb0370","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2147\/OTT.S288422","article-title":"Increased collagen type V \u03b12 (COL5A2) in colorectal cancer is associated with poor prognosis and tumor progression","author":"Wang","year":"2021","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.jconrel.2025.114042_bb0375","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10585-019-09966-1","article-title":"The extracellular matrix in tumor progression and metastasis","volume":"36","author":"Eble","year":"2019","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.jconrel.2025.114042_bb0380","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coph.2017.06.003","article-title":"The good and bad of targeting cancer-associated extracellular matrix","volume":"35","author":"Sangaletti","year":"2017","journal-title":"Curr. Opin. Pharmacol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925006637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925006637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:24:30Z","timestamp":1778945070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925006637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":76,"alternative-id":["S0168365925006637"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114042","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor efficacy achieved by targeting PEGylated nanomedicines to netrin-1 in the extracellular matrix or EphA2 on the cancer cell membrane","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114042"}}